<DOC>
	<DOCNO>NCT01835015</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , serum pharmacokinetics CLG561 subject advance age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>Pharmacokinetics CLG561 Patients With Advanced Age-Related Macular Degeneration</brief_title>
	<detailed_description>Subjects divide 5 cohort , subject cohort administer single IVT dose CLG561 1 5 concentration level A-E , A=lowest E=highest . All subject receive active CLG561 . Progress one cohort next time-lagged allow safety review . Dosing also time-lagged within cohort . Only one eye ( designate study eye ) dose per subject . Post-dose safety assessment ocular examination occur immediately IVT injection continue throughout outpatient visit pre-determined timepoints . Collection post-injection blood sample begin IVT injection pre-determined timepoints . Subjects follow 84 day .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Diagnosis agerelated macular degeneration study eye , specify protocol . Poor visual acuity study eye , specify protocol . Willing receive meningitis pneumonia vaccination least 2 week prior study treatment . Females must postmenopausal and/or surgically sterile . Other protocoldefined inclusion criterion may apply . Treatments study eye within 28 day prior study treatment , specify protocol . Any disease medication expect cause systemic ocular immunosuppression . Participation another interventional clinical study use experimental treatment AMD within 12 week prior study treatment . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>First human</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Serum PK</keyword>
	<keyword>Intravitreal ( IVT )</keyword>
	<keyword>Age-related macular degeneration</keyword>
	<keyword>AMD</keyword>
	<keyword>Geographic Atrophy</keyword>
	<keyword>Choroidal neovascularization</keyword>
</DOC>